Adlarity® (donepezil transdermal system) is FDA approved to treat mild, moderate, and severe Alzheimer-type dementia. It is the first once-weekly donepezil patch approved for this use in the United States.
- Made by Corium, Adlarity comes in 5mg/day and 10mg/day
- Recommended initial dosing is one 5mg/day patch applied per week. If needed, the dose can be increased after 4-6 weeks to one 10mg/day patch each week.
- Adlarity is expected to launch in the fall of Pricing is not yet available.